ProForma 2.0
Not calculated for this record
MP
Aliases: Mastoparan-L, MP
Normalized sequence
INLKALAALAKKIL
14 amino acids
Release PepDiana-V1-20260620
4
Activity records
2
Source papers
4
Positive
0
Negative / threshold
Cross-layer links
Versioned scientific descriptors
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Molecular weight
Not calculated
Molecular formula
Not calculated
Theoretical pI
Not calculated
Net charge at pH 7
Not calculated
GRAVY
Not calculated
Instability index
Not calculated
Aromaticity
Not calculated
Topological polar surface area
Not calculated
cLogP
Not calculated
Hydrogen-bond donors
Not calculated
Hydrogen-bond acceptors
Not calculated
Rotatable bonds
Not calculated
Method: Not recorded
Tool: Not recorded
Calculated: Not recorded
ProForma 2.0
Not calculated for this record
HELM 2.0
Not calculated for this record
Canonical SMILES
Not calculated for this record
Isomeric SMILES
Not calculated for this record
Paper-level observations
Table 1: Mastoparan (L) HRBC EC50 82.9 ± 3.8 μM
Table 1: Mastoparan (L) RRBC EC50 242.5 ± 2.6 μM
The potential of the stapled MP peptides to non-specifically lyse red blood cells (RBC) was measured and their hemolytic activities (HC50) determined. The peptide MP9 displayed the lowest level of RBC hemolysis.
These stapled peptides were evaluated for cytotoxicity in the CRC cell line CT26 in vitro, IC50 values ranged from 1.11 μM to 9.32 μM. These stapled MP derivatives exhibited either enhanced or same anti-CRC activity, in comparison to the parent MP.
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-003679, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00